The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?
The advent of cyclooxygenase-2 inhibitors has been both a blessing and a curse for pain management. An in-depth understanding of the biological molecules in the arachidonic acid metabolism may alleviate pain without risk.
Haque
Wasim
W
Thrombo Therapeutics Inc., 103 Advanced Technology Center, Edmonton, Alberta, CA, USA. ckubnic@lumc.edu
Fareed
Jawed
J
Wehrmacher
William H
WH
Messmore
Harry L
HL
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D004359:Drug Therapy, Combination; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D020030:Nitric Oxide Donors / Q000009:adverse effects / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy*; D013927:Thrombosis / Q000139:chemically induced*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D020030:Nitric Oxide Donors